Ethos Financial Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$459K Sell
2,892
-94
-3% -$14.1K 0.03% 379
2026
Q1
$456K Buy
2,986
+636
+27% +$97.5K 0.03% 329
2025
Q4
$324K Sell
2,350
-846
-26% -$111K 0.02% 373
2025
Q3
$410K Hold
3,196
0.03% 308
2025
Q2
$387K Buy
+3,196
New +$360K 0.03% 301

Other funds holding NVS

Ethos Financial Group's NVS Position: Q2 2026 in Review

Ethos Financial Group reduced its Novartis (NVS) stake by 3.1% in Q2 2026, selling an estimated $14.1K and leaving 2,892 shares worth $459K. The position accounts for 0.03% of the portfolio, ranked #379.

Ethos Financial Group first reported a position in NVS in Q2 2025 and has held it in 5 quarters since. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Ethos Financial Group held 2,892 shares of Novartis worth $459K as of Q2 2026.
  • Ethos Financial Group sold 94 Novartis shares in Q2 2026, an estimated $14.1K.
  • Novartis made up 0.03% of Ethos Financial Group's portfolio in Q2 2026, its #379 holding.
  • Ethos Financial Group first reported a position in Novartis in Q2 2025 and has held it in 5 quarters since.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Ethos Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.